This AASLD 2018 Hepatitis B Guidance is intended to complement the AASLD 2016
Practice Guidelines for Treatment of Chronic Hepatitis B (1) and update the previous …

Hepatitis B reactivation associated with immune-suppressive and biological therapies is
emerging to be an important cause of morbidity and mortality in patients with current or prior …

To achieve the goal of the World Health Organization to eliminate viral hepatitis as a major
public health threat by 2030, the Chinese Society of Infectious Diseases and the Chinese …

中华医学会感染病学分会,中华医学会肝病学分会 Page 1 +,-. 慢性乙型肝炎防治指南(2019 年版
) 中华医学会感染病学分会,中华医学会肝病学分会 摘要:为了实现世界卫生组织提出的“2030 年 …

Hepatitis due to hepatitis B virus (HBV) reactivation can be serious and potentially fatal, but
is preventable. HBV reactivation is most commonly reported in patients receiving …

Portal hypertension (PH) drives most of the clinical complications in chronic liver diseases.
However, its progression in nonalcoholic steatohepatitis (NASH) and its association with the …

Die Medizin unterliegt einem fortwährenden Entwicklungsprozess, sodass alle Angaben,
insbesondere zu diagnostischen und therapeutischen Verfahren, immer nur dem …

Abstract Purpose of Review Chronic HBV (CHB) remains a global public health problem
with over 257 million people chronically infected worldwide. Without appropriate …

Hepatitis B virus reactivation (HBV-R), which can lead to HBV-related morbidity and
mortality, is a common and well-known complication that occurs during the treatment of non …

In endemic areas, hepatitis C virus (HCV)/hepatitis B virus (HBV) coinfection is common, and
patients with coinfection have a higher risk of developing liver disease such as …